Deuruxolitinib: all 23 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia AreataRecruitingNCT07617597Phase 3
• Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia AreataRecruitingNCT07133308Phase 3
• European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataCompletedNCT05041803Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)CompletedNCT04797650Phase 3Results posted
• A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia AreataCompletedNCT04784533Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)CompletedNCT04518995Phase 3Results posted
• Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia AreataCompletedNCT03941548Phase 2Results posted
• Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia AreataCompletedNCT03811912Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia AreataCompletedNCT03137381Phase 2Results posted
• Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy SubjectsCompletedNCT05478772Phase 1
• Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543CompletedNCT05468749Phase 1
• Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543CompletedNCT05467722Phase 1
• Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy SubjectsCompletedNCT05467709Phase 1
• Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy VolunteersCompletedNCT05467696Phase 1
• A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health VolunteersCompletedNCT05192369Phase 1
• Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult SubjectsCompletedNCT04843540Phase 1
• Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult SubjectsCompletedNCT04743414Phase 1
• Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female SubjectsCompletedNCT04309643Phase 1
• Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male VolunteersCompletedNCT04092712Phase 1
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataActive, not recruitingNCT03898479Phase 2/3
• Food Effect Study of CTP-543 in Healthy VolunteersCompletedNCT03880136Phase 1
• Open-Label Crossover Study Comparing CTP-543 to Jakafi®CompletedNCT02960945Phase 1
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy SubjectsCompletedNCT02777008Phase 1

← Deuruxolitinib overview